We use first and third party cookies to track your browsing habits on our website in order to provide you with better quality and security, and improve the services offered through this website. If users do not explicitly confirm that they consent to the installation of cookies but continue to browse our website, we will assume that they have agreed and we will inform them accordingly about the possibility of blocking or deleting any previously installed cookies by adjusting their browser settings. You can find out more about cookies in our "Cookie Policy"

CONFIRM Cookie Policy


Our own immune system, a powerful weapon in the fight against cancer
Tumor cells develop different ways to suppress or avoid detection by the immune system and continue to grow in an uncontrolled manner. Therefore, one of the most advanced and promising strategies in terms of clinical development is immunotherapy, which stimulates the immune system to recognize and eliminate the tumor.

A significant benefit has been observed in certain tumor types, such as melanoma or lung cancer, with the use of immunotherapeutic drugs such as Opdivo® (nivolumab) or Keytruda® (pembrolizumab).

A new hope for treatment of lung cancer
Despite recent advances in treating other types of cancer with immunotherapy, until recently lung cancer was thought to be immuno-resistant. However, in 2015 the immunotherapy drug Opdivo® was approved for treatment of certain subtypes of lung cancer.

After many years without real alternatives for lung cancer treatment, immunotherapy now holds the promise of real change in the way not only lung cancer, but all types of cancer, are treated.